期刊
BIOANALYSIS
卷 15, 期 23, 页码 1407-1419出版社
Newlands Press Ltd
DOI: 10.4155/bio-2023-0156
关键词
antibody; dried blood spot; ELISA; Gyrolab immunoassay; low-volume sampling; microsampling; Mitra; Tasso-M20; validation
Despite technical and logistical challenges, low-volume sampling technologies, such as Mitra and Tasso-M20, can be used to measure drug concentrations in dried blood samples and convert them to serum concentrations using hematocrit levels. Contract Research Organizations' expertise allows for comparison between different low-volume sampling technologies and provides potential solutions.
While low-volume sampling technologies offer numerous advantages over venipuncture, implementation in clinical trials poses technical and logistical challenges. Bioanalytical methods were validated for measuring the concentration of crenezumab and etrolizumab in dried blood samples collected using Mitra and Tasso-M20. The data generated demonstrate that the concentrations of crenezumab and etrolizumab in dried blood collected by either device could be determined using calibrators prepared in serum. Drug concentrations from dried blood were converted to serum concentrations using patient hematocrit levels. Contract Research Organization experience in sample handling and analysis allowed us to compare differences between various low-volume sampling technologies. This study evaluated challenges and presented potential solutions for use of different low-volume sampling technologies for pharmacokinetic analysis.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据